Serious non-fatal and fatal opioid overdose events in a cohort of hospital patients seen by an addiction consultation service: Secondary analysis of the NavSTAR trial

> Jan Gryczynski, PhD Senior Research Scientist Friends Research Institute Baltimore, USA







LISBON ADDICTIONS 2022

Research Team and Collaborators

Friends Research Institute

- Jan Gryczynski, PhD (PI)
- Courtney Nordeck, PhD
- Robert P. Schwartz, MD
- Shannon Gwin Mitchell, PhD
- Kevin O'Grady, PhD
- Research staff:
 - Mary Beth Morrissey, Yarelix Estrada, Kristen Lewis, Angie McCray, Elizabeth Lertch

RTI International (Economic Analysis)

- Gary Zarkin, PhD
- Laura Dunlap, PhD
- Stephen Orme, MA

University of Maryland Medical Center

- Christopher Welsh, MD
- Anna Marie Rawa, LGSW
- Sarah Sackett, LGSW
- Danielle Fitzhugh, LGSW
- Mike Papa, LCSW-C
- Art Cohen
- The UMMC Addiction Consultation team

Funding Source

• NIDA R01DA037942

Trial Registration

• NCT 02599818











- North America is experiencing a crisis of drug overdose deaths.
- In the USA, over 100,000 people died of drug overdoses in a 12-month period.
 - Opioids (primarily illicit fentanyl) are responsible for most overdoses.
- Substance use disorders are associated with high utilization of hospital services.
 - Avoidable hospitalization is a driver of high healthcare costs in the USA.
 - Hospitalization as a 'reachable moment' for intervention.





- The current study examined (a) fatal and (b) serious non-fatal opioid overdose events in a cohort of hospital patients enrolled in a clinical trial of a Patient Navigation intervention.
 - Secondary analysis of the Navigation Services to Avoid Rehospitalization (NavSTAR) trial.

Annals of Internal Medicine

Original Research

Preventing Hospital Readmission for Patients With Comorbid Substance Use Disorder

A Randomized Trial

Jan Gryczynski, PhD; Courtney D. Nordeck, BA; Christopher Welsh, MD; Shannon G. Mitchell, PhD; Kevin E. O'Grady, PhD; and Robert P. Schwartz, MD Ann Intern Med. 2021;174:899-909. doi:10.7326/M20-5475

NavSTAR study overview

- Randomized trial of Patient Navigation services to link hospitalized medical/surgical patients to services and reduce hospital readmissions.
 - NavSTAR vs. Treatment-as-Usual (TAU)
 - Large urban academic hospital with an addiction consultation service

Inclusion/Exclusion Criteria

Inclusion

- DSM-5 criteria for opioid, cocaine, and/or alcohol use disorder
- Age 18 or older
- Willing and able to provide informed consent

Exclusion

- Currently in SUD treatment
- Non-Baltimore City resident
- Pregnant, or current hospitalization for labor & delivery
- Planned discharge to long-term inpatient care (e.g., hospice)
- Hospitalized for suicide attempt





488 referred by SUD consultation team for

eligibility screening







Participant Characteristics (N=400)





Linkage to MOUD treatment (methadone, buprenorphine, or extended-release naltrexone)



- Participants in the NavSTAR Patient Navigation arm saw better linkage to MOUD treatment post-discharge compared to participants in the TAU arm.
- The treatment linkage effect was immediate.
- Differences continued to persist over time.







TAU NavSTAR



Patients being discharged from hospital with comorbid opioid, cocaine, or alcohol use disorders



Gryczynski J, Nordeck CD, Welsh C, et al. Preventing hospital readmission for patients with comorbid substance use disorder: A randomized trial. Ann Intern Med. 6 April 2021. [Epub ahead of print]. doi:10.7326/M20-5475 http://acpjournals.org/doi/10.7326/M20-5475

© 2021 American College of Physicians

Overdose Outcomes

	<u>Fatal</u>	<u>Serious Non-Fatal</u>
Definition	Cause of death is opioid overdose, determined by Medical Examiner	Opioid overdose requiring hospital Emergency Department visit
Data Sources	State death certificate records	Regional Health Information Exchange (all area hospitals)
Time Frame	3.3-5.5 year follow-up	1 year follow-up



Analysis



- Dependent variables: (a) serious non-fatal and (b) fatal opioid overdose
 - (a) Logistic regression (no vs. yes)
 - (b) Proportional hazards Cox regression (survival analysis)
 - Intervention variable: Study arm (NavSTAR vs. TAU)
 - <u>Control variables</u>: Participant sex (male vs. female), race (white vs. non-white), age (in years), and (in the long-term death analysis) prior non-fatal overdose.





- <u>In the first year post-enrollment</u>, there were:
 - 122 non-fatal opioid overdose events requiring hospital care
 - Experienced by 63/400 (15.8%) of participants
 - **17 fatal opioid overdoses** (4.3% of the sample)
- Over the longer-term follow-up (3.3-5.5 years post-enrollment), there were:
 - **52 fatal opioid overdoses** (13% of the sample)

Results



	Serious Non-Fatal Overdose	Fatal Overdose
	(1 year)	(3.3-5.5 years)
	Logistic Regression	Cox Regression
	No vs. Yes (1 or more event)	Time-to-Event
	Odds Ratio [95% CI]	Hazard Ratio [95% CI]
Female Sex (ref= Male)	1.45 [0.82, 2.56]; <i>P</i> = 0.20	1.21 [0.68, 2.14]; <i>P</i> = 0.51
Non-White Race (ref= White)	0.92 [0.51, 1.69]; <i>P</i> = 0.80	0.63 [0.35, 1.16]; <i>P</i> = 0.14
Age (years)	1.00 [0.98, 1.03]; <i>P</i> = 0.76	1.01 [0.98, 1.04]; <i>P</i> = 0.43
NavSTAR Intervention (ref= TAU)	0.50 [0.29, 0.88]; <i>P</i> = 0.017	0.74 [0.42, 1.30]; <i>P</i> = 0.29
Prior Serious Non-Fatal Overdose (ref= No)	-	1.75 [0.92, 3.31]; <i>P</i> = 0.087

Results Summary



- Participants in the NavSTAR arm were less likely than TAU participants to experience non-fatal opioid overdose requiring acute hospital care.
 - Odds Ratio= 0.50 [95% CI= 0.29, 0.88]; *P*=0.017
- There were no significant differences between study arms on fatal overdose.
- No significant differences by participant race, sex, or age (*P*s> 0.10).
- The association between non-fatal opioid overdose and subsequent fatal overdose did not reach statistical significance (HR=1.75 [0.92, 3.31]; *P*= 0.087).





- Opioid overdose events were common in this sample of hospital patients with comorbid substance use disorders.
- This indicates a high level of need for harm reduction and treatment linkage services.
- The NavSTAR Patient Navigation intervention reduced the likelihood of serious non-fatal opioid overdose, but did not impact fatal opioid overdoses.





- Strengths include the RCT design, linkage to objective records, and long-term follow-up.
- Limitations include recruitment from a single site, and a relatively small sample.
- Future research directions:
 - Large, multi-site RCT
 - Implement and scale up Patient Navigation services in hospitals; emphasis on overdose prevention

Thank you!

Jan Gryczynski, PhD Senior Research Scientist Friends Research Institute jgryczynski@friendsresearch.org